Changes

|}

===Prevalence===

The prevalence of diabetes( Both type I and type II ) in U.S. during the years 1980 to 2005, increased from 5.6 million to 15.8 million (Figure 4). Especially people aged from 65 to 74 had the highest prevalence compared to other age groups (Figure 5). The prevalence of the disease was similar in both men and women till the year 1998 but from 1999, the prevalence of the disease increased highly in men compared to females (Figure 6).

===Product pipeline===

{|border="2" cellspacing="0" cellpadding="4" width="100%"

|align = "center" bgcolor = "#FFFF99" colspan = "3" |<font size = "4">'''Product Pipeline'''</font>

|align = "center"|Gastrin <nowiki>+</nowiki> DPP IV Inhibitor

|align = "center"|<font color="#0000FF"><u>[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]</u></font>

|-

|-

|colspan = "3"|<font color="#FF6600">'''Insulin sensitizer'''</font>

|-

|-

|align = "center"|<font color="#0000FF"><u>[http://www.nicox.com/update/NCX_4016.html NicOx]</u></font>

|align = "center"|2

|-

|align = "center"|<font color="#0000FF"><u>[http://www.novonordisk.com/science/pipeline/rd_pipeline.asp?showid=6 Novo Nordisk]</u></font>

|align = "center"|3

|-

|-

|align = "center"|TH0318

|-

|colspan = "3"|<font color="#FF6600">'''Peroxisome Proliferator-Activated Receptor (PPAR) agonist/analogue'''</font>

|-

|align = "center"|<font color="#0000FF"><u>[http://www.drugs.com/nda/muraglitazar_041223.html Bristol-Myers Squibb ]</u></font>

|align = "center"|3

|-

|align = "center"|<font color="#0000FF"><u>[http://www.osip.com/PSN010 OSI]</u></font>

|align = "center"|&nbsp;

|-

|align = "center"|<font color="#0000FF"><u>[http://www.isispharm.com/product_pipeline.html Isis]</u></font>

|align = "center"|1

|-

|-

|align = "center"|189075

|align = "center"|2

|-

|align = "center"|2

|align = "center"|<font color="#0000FF"><u>[http://www.theratech.com/en/products-therapeutic-peptides/pipeline.php Theratechnolgies]</u></font>

|align = "center"|&nbsp;

|-

|align = "center"|TRX4

|align = "center"|<font color="#0000FF"><u>[http://www.btgplc.com/PartneredDevelopment/240/TRX4.html BTG]</u></font>

|align = "center"|2

|-

|align = "center"|AMG 221

|align = "center"|1

|-

|-

|align = "center"|Glen Allen

|align = "center"|Orphan Drug Status

|-

|-

|-

|align = "center"|Nateglinide with insulin sensitizers

|-

|-

|-

|-

|-

|align = "center"|2

|-

|-

|-

|-

|align = "center"|R 1499

|align = "center"|1

|-

|align = "center"|R1438

|align = "center"|2

|-

|align = "center"|R1440

|align = "center"|2

|align = "center"|Neurocrine Biosciences

|align = "center"|2

|-

|align = "center"|<font color="#0000FF"><u>[http://www.merck.com/finance/pipeline.swf Merck]</u></font>

|align = "center"|2

|-

|}

==Intellectual Property==

===Top players and IPC classes===

====IPC code definition====

===Geographical Distribution and Treatment Approaches===

===IP activity and Treatment Approaches===

* [http://www.conferencealerts.com/seeconf.mv?q=ca13a3h0 7th International Diabetes Federation Western Pacific Region Congress] at Wellington, New Zealand on 30 Mar 2008.

* [http://debussy.hon.ch/cgi-bin/confevent?aff2+CONF07692+Diabetes_Mellitus 1st International Conference on Advanced Technologies & Treatments for Diabetes] at Czech Republic during 27 Feb to 01 Mar 2008.

* [http://www.goingtomeet.com/conventions/details/15113 7th International Conference for Clinical Endocrinology,Diabetes and Infertility] at Egypt during Sep-06-2007.

* [http://www.diabetes.ca/section_professionals/confindex.asp CDA/CSEM Professional Conference and Annual Meetings] at British Columbia during October 24-27, 2007.

#[http://www.amylin.com/pipeline/symlin.cfm Amyline] analogue (Pramlinitide) was combined with Insulin for treatment of Type 2 DM and results were favorable.

# Continuous glucose monitoring using implanted glucose sensors is a step forward in evolving technology. Yet it is still very expensive and best for highly trained patients on intensive insulin therapy.